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Abstract
p38 mitogen-activated protein kinase (MAPK) is an essential kinase involved in myogenic differentiation. Although many
substrates of p38 MAPK have been identified, little is known about its upstream activators during myogenic differentiation.
TRAF6 is known to function in cytokine signaling during inflammatory responses. However, not much is known about its
role in myogenic differentiation and muscle regeneration. We showed here that TRAF6 and its intrinsic ubiquitin E3 ligase
activity are required for myogenic differentiation. In mouse myoblasts, knockdown of TRAF6 compromised the p38 MAPK
and Akt pathways, while deliberate activation of either pathway rescued the differentiation defect caused by TRAF6
knockdown. TAK1 acted as a key signal transducer downstream of TRAF6 in myogenic differentiation. In vivo, knockdown of
TRAF6 in mouse muscles compromised the injury-induced muscle regeneration without impairing macrophage infiltration
and myoblast proliferation. Collectively, we demonstrated that TRAF6 promotes myogenic differentiation and muscle
regeneration via the TAK1/p38 MAPK and Akt pathways.
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Introduction
Vertebrate skeletal muscle differentiation is regulated by
multiple factors and intracellular signaling pathways [1–3]. The
myogenic regulatory factors (MRFs) consisting of MyoD, Myf5,
myogenin, and MRF4, and the myocyte enhancer factor 2s
(MEF2s) consisting of MEF2A, MEF2B, MEF2C, and MEF2D,
are two best-characterized families of transcription factors
controlling the myogenic differentiation program [4–6]. In muscle
cells, MRFs form heterodimers with gene E2A products (i.e., E12
or E47). Together, they specifically bind to a consensus DNA
sequence called an E box [4]. MEF2 proteins form homo or
heterodimers among themselves and the dimers bind to a
consensus A/T-rich sequence called a MEF2 site [6,7]. The
activities of MRFs and MEF2s are in turn controlled by multiple
intracellular signaling pathways that include the phosphatidylino-
sitol 3-kinase (PI3K)/Akt- and the p38 mitogen-activated protein
kinase (MAPK)-mediated pathways. The PI3K/Akt-mediated
pathway is mainly activated by insulin-like growth factors (IGFs)
and is known to transcriptionally regulate the expression of the
myogenin gene [8–11]. Downstream of Akt, Foxo1a was implicated
as a key transcription factor negatively involved in myogenic
differentiation [12,13]. In addition to the PI3K/Akt pathway, the
p38 MAPK pathway is also known to promote myogenic
differentiation via multiple mechanisms [14,15]. p38 MAPK
directly phosphorylates MEF2 and enhances its transcriptional
activity [16–18]. p38 MAPK also phosphorylates E47, promotes
its interaction with MyoD, and enhances the transcriptional
activity of MyoD/E47 [19]. In addition, p38 MAPK could also
phosphorylate BAF60 and facilitates the recruitment of the SWI/
SNF complex to the promoters of muscle-specific genes [20].
Several isoforms of p38 MAPK, including p38a, p38b and p38c,
are known to participate in myogenic differentiation [21,22].
Upstream of p38 MAPK, MKK3 and MKK6, two p38-specific
MAPK kinases (MAP2Ks), are known to be involved in myogenic
differentiation [17,23]. Recently, TAK1, a MAP2K kinase
(MAP3K), was also implicated in myogenic differentiation [24].
TAK1 plays a critical role in pro-inflammatory cytokine (e.g.,
interleukin-1b, tumor necrosis factor a) and toll-like receptor
(TLR)-mediated signaling pathways [25–27]. In mammalian cells,
TAK1 associates with TAB1/TAB2/TAB3 and is activated by
TRAF6 in a Lys63-linked polyubiquitin chain-dependent manner
[25,26]. TRAF6 is a member of the TRAF family proteins that
mainly function in IL-1R/TLR-mediated signaling pathways
[26,28]. In TRAF6-mediated signaling pathways, ubiquitination
plays a very important role [25,29]. Together with Ubc13 and
Uev1A, TRAF6 catalyzes the synthesis of lysine-63 (K63)-linked
polyubiquitin chain [29]. TAK1 is activated in a polyubiquitin and
TRAF6-dependent manner [29]. Unexpectedly, unanchored K63-
linked polyubiquitin chains were found to be sufficient in
activating TAK1 in vitro [30]. In the TAK1/TAB complexes,
TAB2 binds preferentially to K63-linked polyubiquitin chains,
resulting in autophosphorylation of TAK1 at S187 and its
subsequent activation [31]. Activated TAK1 phosphorylates and
activates MKK3/MKK6, which in turn activate the p38 MAPK
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phosphorylating and activating IkB kinase (IKK) which in turn
phosphorylates IkB and induces its ubiquitination and degradation
by the proteosome-dependent degradation machinery [29].
Recently, TRAF6 was also found to catalyze direct Akt
ubiquitination, which is essential for Akt membrane recruitment
and its phosphorylation at T308 and S473 [32]. This study further
extends the roles of TRAF6 in cell survival and oncogenic
signaling.
In addition to a well-established role of TRAF6 in IL-1R/TLR-
mediated signaling pathways during inflammation, a recent report
has also implicated TRAF6 in muscle atrophy induced by
denervation or cachexia [33]. However, not much is known about
its role in myogenesis. In the current study, we showed that
TRAF6 is specifically involved in myogenic differentiation.
Knockdown of TRAF6 in myoblasts inhibited myogenic differen-
tiation in a p38 MAPK- and Akt-dependent manner. Deliberate
activation of either pathway rescued the differentiation defect
caused by TRAF6 knockdown, suggesting that both pathways
mediate the myogenic effect of TRAF6. Consistently, TAK1 was
also found to function downstream of TRAF6 in myogenic
differentiation. When TRAF6 was knocked down in vivo, it also
inhibited the injury-induced muscle regeneration. Collectively, our
work showed that TRAF6 promotes myogenic differentiation and
muscle regeneration.
Results
Knockdown of TRAF6 inhibits myogenic differentiation
To explore potential roles of TRAF proteins in myogenic
differentiation, we first focused on TRAF2 and TRAF6, the two
best-characterized members in the TRAF family. Two specific
siRNAs targeting different regions of either TRAF2 or TRAF6
genes were designed and used to transfect C2C12 cells. Cells were
induced to differentiate and cellular proteins were prepared 24 or
48 hours after induction. As shown in Fig. 1A and 1B, both the
TRAF2 and TRAF6 siRNAs were effective in knocking down their
intended targets. However, only the TRAF6-siRNAs specifically
inhibited the expression of myogenin and myosin heavy chain
(MHC), two muscle-specific proteins frequently used as early and
late differentiation markers respectively (Fig. 1A). In contrast, two
TRAF2-siRNAs had no such effects (Fig. 1B). The TRAF6-siRNA
also inhibited the activity of several myogenic luciferase reporter
genes including G133-luc, a reporter driven by 133 base-pair mouse
proximal myogenin promoter; 36MEF2-luc, a MEF2-dependent
reporter with three tandem repeats of a MEF2 site; and 4RE-luc,
an MRF-dependent reporter with four tandem repeats of an E box
(Fig. 1C) [11]. Our data suggested that TRAF6 is required for the
normal myogenic function of MRFs and MEF2s as well as the
expression of the myogenin gene. Consistently, by phase-contrast and
fluorescent microscopy, we showed that knockdown of TRAF6
compromised the formation of multinucleated, MHC-positive
myotubes in C2C12 cells (Fig. 1D, E). As C2C12 cells are
immortalized myoblasts, to ascertain the myogenic role of TRAF6,
we also knocked down TRAF6 in proliferating myoblasts freshly
isolated from mouse muscles. These primary myoblasts were known
to be MyoD-positive [34]. As shown in Fig. 1F and G, specific
knockdown of TRAF6 in primary myoblasts inhibited their
differentiation as evidenced by greatly reduced number of
multinucleated, MHC-positive myotubes. To further exclude the
possibility that TRAF6-siRNAs inhibited myogenic differentiation
due to their potential ‘‘off-target’’ effects, we performed a ‘‘rescue’’
experiment. We first co-transfected C2C12 cells with a TRAF6-
siRNA together with a cDNA expression vector encoding human
TRAF6,which wasresistanttothe mouseTRAF6-siRNA due tothe
sequence difference in the siRNA targeting region (our unpublished
data). As shown in Fig. 2A, human TRAF6 effectively rescued the
inhibitory effect of the mouse TRAF6-siRNA as evidenced by re-
elevated expression of myogenin and MHC (lane 3).
The E3 ligase activity of TRAF6 is required for myogenic
differentiation
Although TRAF6 is an established ubiquitinE3 ligase[35], it was
unclear whether its E3 ligase activity was involved in myogenic
differentiation or not. To address this issue, we first transfected
C2C12 cells with an expression vector encoding either the wild-type
or an E3 ligase-defective mutant TRAF6 (i.e., TRAF6-C70A) [32].
As shown in Fig. 2B, the two constructs had opposite effects: while
the wild-type TRAF6 slightly enhanced the expression levels of
myogenin, TRAF6-C70A reduced levels of myogenin compared to
the control. This suggested that the mutant TRAF6 competed with
the endogenous TRAF6 and compromised its function. Consistent-
ly, when co-transfected with G133-luc, the wild-type TRAF6
enhanced, while TRAF6-C70A inhibited, the activity of the
reporter (Fig. 2C). Furthermore, we asked whether TRAF6-C70A
could rescue the differentiation defect caused by the TRAF6-
siRNA. We co-transfected C2C12 cells with either the GFP-siRNA
or TRAF6-siRNA together with an empty vector or a TRAF6-
C70A-expressing vector. As shown in Fig. 2D, TRAF6-C70A failed
to rescue the differentiation defect caused by TRAF6 knockdown.
Collectively, our data above suggested that the E3 ligase activity of
TRAF6 is required during myogenic differentiation.
TAK1 acts downstream of TRAF6 in myogenic
differentiation
To identify downstream mediators of TRAF6 in myogenic
differentiation, we turned to TAK1, a member of the MAP2K
kinase (MAP3K) family and a well-established downstream target
of TRAF6 [25,26]. As expected, we found that two siRNAs
targeting different regions of the TAK1 gene could effectively
inhibit myogenic differentiation as evidenced by decreased
expression of myogenin and MHC (Fig. 3A). As a control, we
also designed an siRNA targeting MEKK2, another member of
the MAP3K family [36]. As shown in Fig. 3B, the MEKK2-siRNA
did not inhibit the expression levels of myogenin or MHC. In fact,
the MEKK2-siRNA even slightly promoted the expression of both
myogenin and MHC (Fig. 3B). Consistently, when a TAK1-
siRNA was transfected into C2C12 cells or primary myoblasts, it
greatly decreased the number and size of MHC-positive myotubes
(Fig. 3C–F). To test whether TAK1 functions downstream of
TRAF6, we transfected C2C12 cells with a TRAF6-expressing
plasmid with or without the TAK1-siRNA. Consistent with the
data in Fig. 2B, TRAF6 enhanced the expression of myogenin at
both the protein and mRNA levels (Fig. 3G, H). However, this
stimulatory effect was abrogated when TAK1 was knocked down.
Collectively, our data showed that TAK1 is a key downstream
mediator of TRAF6 involved in myogenic differentiation.
The kinase activity of TAK1 is required for myogenic
differentiation
Although our data above showed that TAK1 is required for
myogenic differentiation, it remained unclear whether its kinase
activity is required in this process or not. To address this issue, we
first generated two siRNA-resistant TAK1 expression constructs:
one encoding the wild-type protein (i.e. SR-Wt), and the other
encoding a kinase-dead mutant (i.e. SR-KW) [37]. We then
transfected C2C12 cells with the TAK1-siRNA together with one
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both TAK1 constructs were expressed at similar levels and were
indeed resistant to the TAK1-siRNA. However, only the wild-type
TAK1 (lane 3), but not the kinase-dead TAK1 (lane 4), was able to
effectively rescue the reduction in MHC levels caused by the
TAK1-siRNA (Fig. 4B). Moreover, using an antibody specifically
recognizing the autophosphorylated form of TAK1 (i.e., the active
TAK1) [38], we showed that the levels of the active TAK1 in
C2C12 cells indeed increased upon myogenic differentiation
(Fig. 4C), which paralleled an increase in the levels of the active
p38 MAPK in differentiating myoblasts. This result was consistent
with the data from the ‘‘rescue’’ experiment.
Both p38 MAPK and Akt mediate the effect of TRAF6
during myogenic differentiation
To identify intracellular signaling pathways activated by
TRAF6 in myogenic differentiation, we first turned to p38 MAPK
and Akt which are known to be activated by TRAF6 [32,39]. In
the first set of experiments, we studied the impact of TRAF6
knockdown on the activation status of Akt and p38 MAPK. As
shown in Fig. 5A, the siRNA-mediated TRAF6 knockdown
reduced the levels of Akt phosphorylation at Thr308 and Ser473,
which are required for maximal Akt activation [40]. Moreover,
knockdown of TRAF6 also decreased the levels of the phosphor-
ylated (i.e., active) p38 MAPK. In the second set of experiments,
we tested whether deliberate activation of either p38 MAPK or
Akt could rescue the differentiation defect caused by the TRAF6-
siRNA. To do so, we co-transfected C2C12 cells with the TRAF6-
siRNA together with an expression vector encoding MKK6EE
that constitutively activated p38 MAPK, MEK1ca that constitu-
tively activated ERK, or a constitutively active Akt (i.e.,
myristoylated Akt). As shown in Fig. 5B and 5C, only the
constitutively active MKK6EE (Fig. 5B) and Akt (Fig. 5C)
effectively reversed the inhibitory effect of the TRAF6-siRNA
Figure 1. TRAF6 was required for myogenic differentiation. (A, B) C2C12 cells were transfected with a GFP-siRNA, two different TRAF6-siRNAs,
or two different TRAF2-siRNAs as indicated. (C) C2C12 cells were transfected in triplicate with either the GFP-siRNA or TRAF6-siRNA together with
different luciferase reporter constructs as indicated. Twenty-four hours (h) after transfection, cells were induced to differentiate for 24 h or 48 h
before harvest. For (A, B), 60 mg of whole cell extracts (WCE) were subjected to SDS-PAGE and Western blot (WB) analysis for various proteins
indicated on the left side of the panels. For (C), cells were harvested after 24 h in DM and WCE were prepared and subjected to luciferase assays. Fold
change was calculated as the ratio of the luciferase activity of the TRAF6-siRNA transfected cells over that of the GFP-siRNA transfected cells. The
results were presented as mean+s.d. (D–G) C2C12 cells (D, E) or primary myoblasts (F, G) were transfected with the GFP-siRNA or TRAF6-siRNA. Cells
were fixed at DM 48 h and subjected to immunostaining for myosin heavy chain (MHC) or MyoD. The nuclei were counterstained with DAPI. In (E, G),
the percentage of MHC-positive cells was calculated as the ratio of the number of nuclei in MHC-positive cells over that of DAPI-positive nuclei (E) or
MyoD-positive nuclei (G). Cells from five different microscopic fields were counted and the results were presented as mean+s.d.
doi:10.1371/journal.pone.0034081.g001
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constitutively active MEK1ca had no such effects (Fig. 5B, lane 4).
Taken together, our data above suggested that both p38 MAPK
and Akt mediated the effect of TRAF6 during myogenic
differentiation.
TRAF6 knockdown impairs the injury-induced muscle
regeneration
To further explore the myogenic role of TRAF6 in vivo, we
resorted to the cardiotoxin (CTX)-induced muscle injury and
regeneration model [34]. The GFP-siRNA or TRAF6-siRNA
mixed with liposome was directly injected into the CTX-injured
tibialis anterior (TA) muscles of adult mice followed by
electroporation for multiple times. Based on a fluorescent dye-
labeled control siRNA, we showed that this method could
efficiently deliver siRNA into TA muscles (Fig.S1A). The TA
muscles were dissected out at different time points to monitor the
progress of the regeneration. As shown in Fig. 6A, at both day 3
and day 5 after injury, the TRAF6-siRNA could effectively reduce
the TRAF6 mRNA levels by about 40%. The mRNA levels of
both myogenin and embryonic MHC (eMHC) were also greatly
reduced by the TRAF6-siRNA (Fig. 6A). Consistently, we found
that the number of newly-formed regenerating myofibers, which
were characterized by either centrally-localized nuclei or expres-
sion of eMHC [34], was also reduced in TA muscles injected with
the TRAF6-siRNA (Fig. 6B, 6C). By Western blotting, we
confirmed that TRAF6 knockdown in muscles reduced the
expression levels of myogenin as well as the levels of the active
p38 MAPK and Akt (Fig. 6D). In contrast, the expression levels of
Pax7 slightly increased. To find out whether the defective muscle
regeneration was due to an inhibitory effect of the TRAF6-siRNA
on myoblast proliferation, we examined the Pax7-positive muscle
precursor cells (MPC) (including muscle satellite cells and
proliferating myoblasts) in regenerating muscles 3 days after
injury. Interestingly, we found that TRAF6 knockdown increased
the number of Pax7-positive MPC (Fig.S1B). To further ascertain
this effect, we knocked down TRAF6 in isolated primary
myoblasts. We found that TRAF6 knockdown indeed promoted
myoblast proliferation as evidenced by an increase in the number
of Pax7-positive cells as well as BrdU-positive cells (Fig.S1C, 1D).
As TRAF6 is expressed in macrophages, it was possible that
TRAF6 knockdown could inadvertently affect macrophage
infiltration, which is a critical early step in muscle regeneration
[41]. As macrophage infiltration peaked in the first two days after
injury, we examined CD68-positive macrophages in regenerating
muscles 2 days after injury. We found that TRAF6 knockdown did
not affect macrophage infiltration (Fig.S2A, 2B). Consistently, by
quantitative RT-PCR analysis, we showed that the mRNA levels
of CD68 and F4/80, both of which are unique markers of
macrophages, were not affected by TRAF6 knockdown (Fig.S2C).
Our data above indicated that TRAF6 is required for muscle
regeneration mainly by promoting myoblast differentiation.
Discussion
The involvement of the p38 MAPK pathway in myogenic
differentiation has been well documented. Multiple myogenic
substrates of p38 MAPK have been identified that could provide
some molecular basis for an indispensable role of p38 MAPK in
myogenesis [14,15]. In contrast to what we already know about
various downstream targets of p38 MAPK, very little is known
about its upstream activators during myogenic differentiation. Our
findings here show that TRAF6 is a key p38 activator in myogenic
differentiation. Interestingly, TRAF2, another related member of
the TRAF family proteins, has no such pro-myogenic effect in our
assays, suggesting that the pro-myogenic effect of TRAF6 is quite
Figure 2. The E3 ligase activity of TRAF6 was required for myogenic differentiation. (A) C2C12 cells were transfected with either the GFP-
siRNA or the TRAF6-siRNA together with an empty vector or a vector encoding human TRAF6 as indicated. (B) C2C12 cells were transfected with
either an empty vector (pcDNA) or an expression vector encoding either the wild-type (WT) or an E3 ligase-defective mutant TRAF6. (C) C2C12 cells
were transfected in triplicate with G133-luc together with pcDNA or an expression vector encoding the wild-type or the mutant human TRAF6.
Twenty-four hours after transfection, cells were switched to DM for another 24 hours. WCEs were prepared and subjected to luciferase assays. Fold
change was calculated as the ratio of the luciferase activity in TRAF6-transfected cells over that in pcDNA-transfected cells. The results were presented
as mean+s.d. (D) C2C12 cells were transfected with the GFP-siRNA or TRAF6-siRNA together with pcDNA or an expression vector encoding the wild
type or mutant human TRAF6. For (A), (B), and (D), cells were harvested at DM 36 h and WCE were subjected to SDS-PAGE and Western blot analysis
for various proteins as indicated.
doi:10.1371/journal.pone.0034081.g002
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implicates TRAF6 in myogenic differentiation [42]. However, no
underlying mechanism was provided in that report. We showed
here that TRAF6 promotes myogenic differentiation mainly by
activating the TAK1/p38 MAPK pathway and the Akt pathway,
as knockdown of TRAF6 reduced the levels of active p38 MAPK
and Akt in myoblasts (Fig. 5). Importantly, deliberate activation of
either the p38 MAPK pathway or Akt pathway could rescue the
differentiation defect caused by TRAF6 knockdown. As an
ubiquitin E3 ligase, TRAF6 is known to be required for activation
of both TAK1 and Akt via distinct mechanisms. For TAK1,
TRAF6 generates unanchored K63-linked polyubiquitin chain
that is bound by TAB2 leading to TAK1 activation [30]. For Akt,
TRAF6 catalyzes direct K63-linked polyubiquitination of Akt to
result in its activation [32]. Interestingly, TAK1 was also shown to
promote Akt activation during myoblast differentiation [24]. This
effect is most likely indirect, as lack of TAK1 did not affect the
IGF1-induced Akt activation in myoblasts. Therefore, the
molecular basis for the involvement of TAK1 in Akt activation
remains to be elucidated.
Other than TRAF6, another well-established upstream p38
activator is Cdo, a cell surface protein known to trigger activation
Figure 3. TAK1 was required for myogenic differentiation. (A, B) C2C12 cells were transfected with various siRNAs as indicated. Cells were
harvested at the indicated time points and WCEs were subjected to SDS-PAGE and Western blot analysis. (C–F) C2C12 cells (C, D) or primary
myoblasts (E, F) were transfected with either the GFP-siRNA or the TAK1-siRNA. Forty-eight hours after induction of differentiation, cells were fixed
and subjected to immunostaining for MHC or MyoD. The nuclei were counterstained with DAPI. In (D, F), the percentage of MHC-positive cells was
calculated the same way as that described in the legend of Fig. 1(E, G). (G, H) C2C12 cells were co-transfected with an empty vector or a TRAF6-
expressing vector together with the GFP-siRNA or TAK1-siRNA as indicated. Twenty-four hours after induction of differentiation, cells were harvested
for subsequent analysis: WCE were subjected to SDS-PAGE and Western blot analysis (G), while total RNA was prepared for RT-qPCR analysis (H) of
relative myogenin gene expression. 1, 2, 3 in (G) and (H) denote the same set of samples.
doi:10.1371/journal.pone.0034081.g003
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during myogenic differentiation [43]. Bnip-2, a scaffold protein for
Cdc42, and JLP, a scaffold molecule for p38 MAPK, were found
to be key signal transducers in mediating the pro-myogenic effect
of Cdo [44,45]. It is unclear whether TRAF6 is involved in the N-
cadherin/Cdo-mediated p38 MAPK pathway during myogenic
differentiation. It is likely that the TRAF6/TAK1 pathway and
the N-cadherin/Cdo pathway are two parallel but non-redundant
pathways, both leading to p38 activation in response to different
signals. More future work is needed to study potential cross-talk
between these two pathways.
The involvement of the pathway consisting of TRAF6/TAK1/
MKK3/6/p38 MAPK in myogenic differentiation further sug-
gests that the potential extracellular stimuli that trigger myoblast
differentiation in vivo may belong to the family of pro-
inflammatory ligands that utilize IL-1R/TLR. This hypothesis is
particularly relevant during injury-induced muscle regeneration in
adult animals, as such pro-inflammatory molecules are quickly
induced and abundantly expressed in damaged muscles. Consis-
tently, in the CTX-induced muscle regeneration model, we
showed that knockdown of TRAF6 by siRNA greatly compro-
mised the regeneration process (Fig. 6B, C). Interestingly, the
proliferation of the Pax7-positive muscle precursor cells (MPC)
was not inhibited by TRAF6 knockdown. In contrast, TRAF6
knockdown slightly promoted expansion of the Pax7-positive MPC
(Fig.S1). This is most likely due to the reduced p38 activity, which
has been causally linked with enhanced proliferation of the Pax7-
positive MPC [46]. This result further strengthens our view that
the regeneration defect caused by TRAF6 knockdown is mainly
due to its role in myoblast terminal differentiation instead of
proliferation of MPC. Moreover, although we are mainly
concerned with the role of TRAF6 in myoblasts here, we cannot
completely rule out a positive role of TRAF6 in inflammatory
cells, especially macrophages that are known to be indispensable
for muscle regeneration [41]. A quick survey of injured muscles
showed that TRAF6 knockdown did not affect macrophage
infiltration into the injured muscles (Fig.S2). Nevertheless, TRAF6
in macrophages could still indirectly contribute to muscle
regeneration by regulating the expression of certain secretable
factors (e.g. cytokines and chemokines) that in turn may regulate
muscle satellite cells. In the future, the use of conditional knockout
mice with TRAF6 specifically deleted in myeloid cells may reveal
additional role of TRAF6 in these inflammatory cells during
muscle regeneration.
F i g u r e4 .T h ek i n a s ea c t i v i t yo fT A K 1w a sr e q u i r e df o r
myogenic differentiation. (A, B) C2C12 cells were co-transfected
with a control siRNA or TAK1-siRNA together with various expression
vectors as indicated. Wt: Flag-TAK1; SR-Wt: an siRNA-resistant wild-type
TAK1; SR-KW: an siRNA-resistant kinase-dead TAK1. Cells were harvested
at DM 36 h. The minus sign means that a control siRNA or an empty
vector was used. (C) C2C12 cells were induced to differentiate in DM for
2 to 6 hours. WCE from (A–C) were prepared and subjected to SDS-
PAGE and Western blot analysis for various proteins as indicated.
doi:10.1371/journal.pone.0034081.g004
Figure 5. Both p38 MAPK and Akt mediated the effect of TRAF6
during myogenic differentiation. (A–C) C2C12 cells were transfect-
ed with the GFP-siRNA or TRAF6-siRNAs with or without various cDNA
expression vectors as indicated. (A). Cells were harvested 24 hours after
transfection. (B, C) Twenty-four hours after transfection, cells were
induced to differentiate in DM for another 36 hours before harvest.
WCEs from (A–C) were subjected to SDS-PAGE and Western blot
analysis for various proteins as indicated. MKK6EE, MEK1ca and Aktca
are the constitutively active mutants of MKK6, MEK1, and Akt
respectively. xp: Xpress-tag.
doi:10.1371/journal.pone.0034081.g005
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One can envision that small molecules that trigger the activation of
the TRAF6/TAK1/p38 MAPK pathway and TRAF6-Akt
pathway are likely beneficial in promoting muscle regeneration
in response to various injuries.
Materials and Methods
Animal handling
All C57BL/6J mice were maintained and handled in accor-
dance with the protocols approved by the Animal Ethics
Committee of the Hong Kong University of Science &
Technology and the Department of Health of the Hong Kong
Special Administrative Region [Ref No: (11-28) in DH/HA&P/8/
2/2 Pt.3].
Cell line, DNA constructs and reagents
C2C12 mouse myoblasts (American Type Culture Collection,
Manassas, VA) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 20% fetal bovine serum
(FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin
(growth medium, or GM) in a humidified incubator at 37uC with
5% CO2. To induce differentiation, near-confluent C2C12 cells
were grown in DMEM supplemented with 2% horse serum
(differentiation medium, or DM). G133-luc, 4RE-luc, 3MEF2-luc
HA-MKK6EE, HA-TRAF6, Flag-TAK1(wt), and the kinase-dead
Flag-TAK1(KW) were described previously [17,47,48]. Silent
mutation was introduced into Flag-TAK1(wt) and Flag-
TAK1(KW) constructs to generate the siRNA-resistant Flag-
TAK1(SR-Wt) and Flag-TAK1(SR-KW) respectively using the
following oligonucleotide: 59- CGA GGA AAT TGA TTA CAA
GGA GAT CGA GGT GGA AGA GG -39 (top strand). TRAF6-
C70A was a gift from Dr. Huikuan Lin (M.D. Anderson Cancer
Center, Houston, TX). 49,6-diamidino-2-phenylindole (DAPI) and
cardiotoxin (CTX) were from Sigma (Sigma-Aldrich, St.Louis,
MO) and Latoxan (Latoxan, Valence, France) respectively. All
DNA recombinant work follows the National Institutes of Health
guidelines.
siRNA transfection
The following siRNAs were used: EGFP-siRNA (59
GCTGACCCTGAAGTTCATC 39); TAK1-siRNAs (1# 59
GAGATCGACTACAAGGAGA 39;2 # 59 CCATTATAA-
CAGTTCATGA 39); MEKK2-siRNAs (1# 59 GCACTAG-
Figure 6. Knockdown of TRAF6 impaired the CTX-induced muscle regeneration. (A–D) Tibialis anterior (TA) muscles of adult mice were
injected with 30 mlo f1 0mM CTX. One day after CTX injection, the GFP-siRNA and TRAF6-siRNA mixed with liposome were injected into the left and
right injured TA muscles respectively once per day. TA muscles were collected at day (D) 3 and day 5 after CTX injection. The total RNA, muscle
sections, or WCEs were prepared and subjected to RT-qPCR (A), hematoxylin-eosin staining (B), immunostaining (C), or SDS-PAGE and Western blot
analysis (D). The number of myofibers with central nuclei (B) or the number of eMHC-positive myofibers (C) was calculated from five different
microscopic fields. The results were presented as mean+s.d. CTX: cardiotoxin. eMHC: embryonic MHC.
doi:10.1371/journal.pone.0034081.g006
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39); and TRAF6 (1# 59 ACCACGAAGAGGTCATGGA 39;2 #
59 TAAGCCAACCAGTTACTTT 39). siRNAs were synthesized
at either Dharmacon Inc. or RiboBio Co, Ltd (Guangzhou,
China). A fluorescent dye-labeled control siRNA (Cy3-Ncontrol)
used to monitor the transfection efficiency was purchased from
RiboBio Co, Ltd. To deliver oligonucleotide-based siRNAs into
cells, 40–60% confluent C2C12 cells were transfected with 20 nM
siRNA using lipofectamine RNAiMAX (Invitrogen, Carlsbad,
CA). Briefly, for 3.5 cm dishes, siRNAs were diluted in 100 mlo f
Optimal DMEM and then 4 ml of lipofectamine RNAiMAX was
added directly into the diluted siRNA. The mixture was left to
stand at room temperature for 20 min before being added to cells.
Transient transfection of plasmids and cell lysis
Transient transfection was performed using Lipofectamine/
PLUS Reagents (Invitrogen) according to the manufacturer’s
instruction. Briefly, 6 ml of PLUS Reagent was mixed with 1 mgo f
DNA diluted in 100 ml of DMEM without serum and antibiotics
for 15 min at room temperature. Then 100 ml of DMEM
containing 4 ml of Lipofectamine was added to it and incubated
for another 15 min. The mixture was added to cells in 3.5 cm
culture dishes, and incubated at 37uC for 3 hours before being
removed and replaced with normal growth medium. Cells were
lysed on ice for 10 min in the lysis buffer (50 mM Hepes at
pH 7.6, 10% glycerol, 1% Triton X-100, 150 mM NaCl, 1 mM
EGTA, 1.5 mM MgCl2, 100 mM NaF, 20 mM PNPP, 20 mM b-
glycerol phosphate, 2 mM dithiothreitol (DTT), 50 mM sodium
vanadate, 0.5 mM phenylmethylsulfonyl fluoride, 2 mg/ml apro-
tinin, 0.5 mg/ml leupeptin, 0.7 mg/ml pepstatin), followed by
removal of insoluble debris in a bench-top centrifuge at 12,0006g
for 2 min to obtain soluble whole cell extracts (WCE).
Antibodies, immunostaining, and Western blotting
The following antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA): anti-myogenin (F5D), anti-b-actin, anti-MyoD
(M-318), anti-MEF2 (c-21), anti-TAK1(M-579), and anti-TRAF6
(D-10). Anti-total p38, anti-phospho-p38 (Thr180/Tyr182), anti-
phospho-TAK1 (Thr187), anti-phospho-JNK (Thr183/Tyr185),
anti-total JNK, anti-phospho-ERK(Thr202/Tyr204), and anti-
total ERK were purchased from Cell Signaling Inc (Danvers, MA).
Anti-CD68 was purchased from AbD Serotec (Oxford, UK). For
immunostaining, cells were first fixed in 4% paraformaldehyde for
15 min, then permeabilized in 0.2% Triton X-100 for 15 min and
blocked in 5% BSA in PBS for 1 hour. Cells were then incubated
with a primary antibody overnight, washed three times with PBS,
and re-incubated with a Rhodamine- or Fluorescein-conjugated
secondary antibody (Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA) for one hour. 100 ng/ml of DAPI was then
added for another 10 minutes to stain the nuclei. Fluorescence
microscopy was performed using an Olympus IX70 microscope
linked to a charge-coupled device digital camera (Spot RT,
Diagnostic Instruments Inc., Sterling Heights, MI). Western
blotting was performed as described previously [11].
Luciferase reporter assays
Cell lysates (10 ml) were mixed with 150 ml of the assay buffer
(0.1 M Tris-acetate, pH 7.8, 1 mM EDTA, 10 mM Mg(OAc)2)
supplemented with 66 mM luciferin and 2 mM ATP. Total light
emission was measured in an LB9507 luminometer (EG&G
Berthold). The luciferase units of each sample were normalized
against the protein concentration determined by a protein assay
reagent (BioRad).
Preparation of mouse primary myoblasts
We followed a protocol from Dr. G Pavlath’s laboratory.
Briefly, Two month-old C57BL/6J mice were sacrificed by
cervical dislocation and then rinsed with 70% ethanol. All the
limb muscles were dissected away from the skins and bones,
minced into fine pieces with scissors, and transferred to 40 ml PBS
in a 50 ml centrifuge tube. After mixing followed by centrifugation
at 3006 g for 4 min, the supernatants with blood and fat were
removed. 10 ml of DMEM and 1 ml of 1% pronase were added to
the tube containing minced tissues. The tube was incubated at
37uC with continuous shaking for 1.5 hours. After centrifugation
at 3006g for 5 min, the enzyme solution was removed, and the
pellets were resuspended in 5,10 ml DMEM, and triturated with
a pipet to loosen cells. The supernatants were passed through a
100 mm filter. The myoblasts were pelleted by centrifugation at
3006 g for 5 min and resuspended in 10 ml of growth media
(F10+20% FBS+5 ng/ml bFGF) in non-coated plates. Fibroblasts
were allowed to ‘‘settle down’’ for 45,60 mins. The floating
myoblasts in media were transferred to a Matrigel (BD
Biosciences)-coated plate. The growth media were changed every
36 hours. Myoblasts were induced to differentiate in DM (DMEM
with 5% horse serum).
Delivery of siRNA into skeletal muscles and hematoxylin-
eosin staining
Tibialis anterior (TA) muscles of 6–8 week-old C57BL/6J mice
were injected with 30 mlo f1 0mM CTX. One day after the injury,
6 mlo f5 0mM GFP-siRNA or TRAF6-siRNA in OPTI-MED-
IUEM was mixed with 6 ml of RNAiMAX (Invitrogen) and
incubated for 15 min at room temperature. The GFP-siRNA and
TRAF6-siRNA were directly injected into the left and right TA
muscles of the same mice respectively followed by electroporation
using a BTX ECM 830 generator (mode: LV; field strength:
175 V/cm; pulse length: 20 ms; number of pulses: 8) and a pair of
7-mm Tweezertrodes (BTX) with one electrode attached to the
TA muscle and the other to the gastrocnemius muscle of the lower
hind limb. The siRNA injection/electroporation was repeated
once per day for various days before mice were sacrificed and TA
muscles were collected. The isolated TA muscles were subjected to
either total RNA purification or fixed in 4% paraformaldehyde
and sectioned at 6,8 mm on a cryostat (Leica) and then stained
with hematoxylin and eosin.
Quantitative RT-PCR (RT-qPCR)
cDNA was generated from total RNA by ImPromega-II reverse
Transcription System from Promega. Power SYBR Green PCR
Master Mix (Applied Biosystems) was used for real-time PCR.
Primers used were as follows: TRAF6 (forward: 59- AAAGCGA-
GAGATTCTTTCCCTG-39; reverse: 59-ACTGGGGACAATT-
CACTAGAGC-39); myogenin (forward: 59-GCAATGCACTG-
GAGTTCG-39; reverse: 59-ACGATGGACGTAAGGGAGTG-
39); CD68 (forward: 59-ACAGGCAGCACAGT GGACATTC-
39; reverse: 59-ATGAGAGGCAGCAAGAG-39); F4/80 (forward:
59-CCCAGCTTATGCCACCTGCA-39; reverse: 59-TCCAGG-
CCCTGGAACATTGG-39); and the embryonic MHC (eMHC)
(forward: 59-AAAAGGCCATCACTGACGC-39; reverse: 59-
CAGCTCTCTGATCCGTGTCTC-39). The qPCR reaction
was performed in a 7500 Fast Real-time PCR System (Applied
Biosystems). More than 40 cycles of amplification were performed,
with each consisting of a denaturation (95uC; 3 s) and an
annealing/extension (60uC; 30 s) step. Data acquisition and the
analysis of the qPCR assays were performed using the 7500
software (Version 2.0.2; Applied Biosystems).
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Figure S1 TRAF6 knockdown promoted proliferation of
Pax7-positive muscle precursor cells. (A) A Cy3-labeled
control siRNA was mixed with liposome and injected into TA
muscles. Muscle sections were prepared one day or two days after
injection and subjected to fluorescent microscopy. The images
were taken with a 46objective. (B) TA muscles of adult mice were
injected with CTX followed by treatment with the GFP-siRNA
and TRAF6-siRNA as described in the legend of Fig. 6. TA
muscles were collected at day 3 after CTX injection. Muscle
sections were prepared and subjected to immunostaining for Pax7.
The nuclei were counterstained with DAPI. The number of Pax7-
positive cells was calculated from five different microscopic fields
and the results were presented as mean+s.d. (C, D) Primary
myoblasts were transfected with either the GFP-siRNA or
TRAF6-siRNA. Twenty-four hours after transfection, cells were
either left untreated (C) or treated with BrdU (D) for 1.5 hour
before fixation. Cells were then subjected to immunostaining for
Pax7, MyoD, and BrdU. The percentage of the Pax7-positive cells
and the BrdU-positive cells was calculated as the ratio of the
number of Pax7-positive nuclei (C) and BrdU-positive nuclei (D)
over that of DAPI-positive nuclei. Cells from five different
microscopic fields were counted and the results were presented
as mean+s.d.
(TIF)
Figure S2 TRAF6 knockdown did not affect macrophage
infiltration. (A–C) TA muscles of adult mice were injected with
CTX followed by treatment with the GFP-siRNA and TRAF6-
siRNA as described above in the legend of Fig.S1. TA muscles
were collected at day 2 after CTX injection. Non-injured TA
muscles were used as a control. Muscle sections or total RNA were
prepared and subjected to immunostaining for CD68 (A, B) or
RT-qPCR analysis for relative mRNA expression of CD68, F4/
80, and TRAF6 (C). Images in (A) were taken with a 46objective,
while the same images in (B) were taken with a 206objective. The
nuclei were counterstained with DAPI.
(TIF)
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